Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects

被引:122
作者
Goh, WC
Markee, J
Akridge, RE
Meldorf, M
Musey, L
Karchmer, T
Krone, M
Collier, A
Corey, L
Emerman, M
McElrath, MJ
机构
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Program Infect Dis,Sch Med, Seattle, WA 98109 USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Div Mol Med, Seattle, WA 98109 USA
[3] Univ Washington, Sch Med, Dept Med, Seattle, WA 98109 USA
[4] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98109 USA
关键词
D O I
10.1086/314632
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It has been hypothesized that protection against human immunodeficiency virus (HIV)-1 infection may result from either acquired host immunity, inheritance of a dysfunctional CCR5 HIV-1 coreceptor, or a low or attenuated virus inoculum, Thirty-seven HIV-1-uninfected persons engaging in repeated high-risk sexual activity with an HIV-1-infected partner were prospectively studied to determine the contribution of these factors in protecting against HIV-1 transmission. More than one-third (13/36) demonstrated HIV-1-specific cytotoxicity, and this activity significantly correlated with the wild type CCR5 genotype (P = .03), Only 1 subject (3%) demonstrated the homozygous CCR5 32-bp deletion (Delta 32/Delta 32). Median plasma HIV-1 RNA levels from 18 HIV-1-infected sex partners were not statistically different from those of matched infected control patients. These results indicate that inheritance of the Delta 32 CCR5 mutation does not account for the majority of persistently HIV-1-resistant cases, and the presence of cellular immunity in these persons suggests either undetected infection or protective immunity.
引用
收藏
页码:548 / 557
页数:10
相关论文
共 32 条
[31]  
WAHL SM, 1989, J IMMUNOL, V142, P3553
[32]   Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk [J].
Zimmerman, PA ;
BucklerWhite, A ;
Alkhatib, G ;
Spalding, T ;
Kubofcik, J ;
Combadiere, C ;
Weissman, D ;
Cohen, O ;
Rubbert, A ;
Lam, G ;
Vaccarezza, M ;
Kennedy, PE ;
Kumaraswami, V ;
Giorgi, JV ;
Detels, R ;
Hunter, J ;
Chopek, M ;
Berger, EA ;
Fauci, AS ;
Nutman, TB ;
Murphy, PM .
MOLECULAR MEDICINE, 1997, 3 (01) :23-36